Alkem Oncology Launches Cetuxa: Biosimilar for Head and Neck Cancer Treatment

In both India and the rest of the world, head and neck cancers (HNCs) are among the most prevalent malignancies. The Global Cancer Observatory (GLOBOCAN) predicts that 19.3 million new cases of cancer will occur globally in 2020, with India being the third-most affected nation after China and the United States of America. Asia shoulders the majority burden of head and neck cancer cases, accounting for 57.5% of global occurrences, with India contributing a significant 30% to this statistic. Annually, India witnesses approximately 500,000 cases of head and neck cancer, resulting in over 125,000 fatalities.

With the release of Cetuxa, the first biosimilar version of Cetuximab created exclusively for the treatment of head and neck cancer, Alkem Oncology made a ground-breaking announcement.This pioneering drug has been meticulously researched and manufactured by Enzene Biosciences Limited, the biological arm of Alkem Laboratories, showcasing India's prowess in the field of biotechnology and pharmaceutical innovation.
Cetuxa's launch seeks to improve the availability and affordability of a revolutionary cancer treatment for those with head and neck cancer. As a biosimilar of cetuximab, a monoclonal antibody, Cetuxa received approval from the Drugs Controller General of India (DCGI) on January 16, 2023, for this specific indication.
The extracellular domain of the epidermal growth factor receptor (EGFR), a protein that is frequently overexpressed in a variety of human malignancies, including head and neck cancer and colorectal cancer, is where cetuximab works.
By preventing the interaction between EGFR and its endogenous ligand, Cetuxa obstructs the receptor-dependent transduction pathway, leading to several anti-tumor effects.
Cetuxa is dispensed as a single-dose vial containing 100 mg (2 mg/mL) of the medication and is delivered via intravenous infusion. The recommended initial dose is 400 mg/m2, followed by a weekly follow-up dosage of 250 mg/m2.
By offering an indigenous biosimilar that mirrors the efficacy of the original drug, Alkem Oncology and Enzene Biosciences have paved the way for improved access to a life-changing therapy. This development holds immense promise for patients grappling with this aggressive form of cancer, providing them with a ray of hope and a chance at an improved quality of life.
Moreover, Cetuxa's availability at a more affordable cost could potentially alleviate the financial burden faced by patients and their families, ensuring that life-saving treatments are within reach for a larger population. The breakthrough achieved by Alkem Oncology and Enzene Biosciences exemplifies India's growing prowess in the biopharmaceutical industry and reinforces the nation's commitment to advancing healthcare innovation.
The introduction of Cetuxa, the first biosimilar version of Cetuximab for the treatment of head and neck cancer, marks the beginning of a new phase in the struggle against this life-threatening condition.

With India's significant contribution to global head and neck cancer cases, the introduction of an accessible and affordable treatment option like Cetuxa is a game-changer. This innovative biosimilar showcases the nation's ability to develop advanced therapies and provides hope for a brighter future in the battle against head and neck cancer. BioIntel360 suggests that by offering a homegrown solution that replicates the effectiveness of the original drug, Cetuxa demonstrates India's prowess in the field of biopharmaceuticals and highlights its commitment to healthcare innovation.